Clinical Trial

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

Study acronym: REMAIN1
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-12; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06370000
Lead Sponsor Virginia Commonwealth University
Conditions Acute Myeloid Leukemia
Enrollment 12 participants
Start Date 2024-11-07
Primary Completion 2027-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29